
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health is a strong investment opportunity as it has recently launched Befrena, a new derm product with great potential to take market share from the only other competitor in the market. They have also reported strong financials, with a 4.2% beat on total revenue in the second quarter, increased guidance for the third quarter and full year, and plans to accelerate price taking in the second half. Additionally, the company has an impressive innovation pipeline with seven potential blockbuster launches that will contribute to sales growth and margin expansion.
Bears say
Elanco Animal Health is facing intense competition in the animal health market and is being forced to compete through portfolio selling and targeted marketing rather than price. It has recently seen a decline in sales due to competition, and its strategy to accelerate price taking in the second half of 2026 may not be successful as it relies on targeted advertising. Additionally, while the company has a strong pipeline of innovative products, there is uncertainty surrounding their commercial success, which could lead to potential losses in revenue.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares